Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Segmental Overgrowth Disorders Due to PIK3CA
Interventions
DRUG

Sirolimus

Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.

Trial Locations (11)

21079

CHU de DIJON, Dijon

31059

Pôle Cardiovasculaire et Métabolique - Hôpital Larrey, Toulouse

33076

CHU de Bordeaux - GH Pellegrin, Bordeaux

34295

CHRU de Montpellier - Hôpital Saint-Eloi, Montpellier

37044

CHRU de Tours, Tours

44093

Hôpital mère-enfant de Nantes, Nantes

49933

CHU d'Angers, Angers

54511

Hopitaux de Brabois Chu Nancy, Nancy

59037

Hôpital Jeanne de Flandre, Lille

69495

HCL Lyon - CH Lyon Sud, Pierre-Bénite

75015

CHU Paris - Necker, Paris

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT02443818 - Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA | Biotech Hunter | Biotech Hunter